Objectives The aim of this study was to assess the safety and efficacy of long-term low-dose
glucocorticoids (GCs) in RA. Methods A protocolised systematic review and meta-analysis …

Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to inform the 2022 …

Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An …

Objectives To characterise infections in patients with rheumatoid arthritis (RA) in ORAL
Surveillance. Methods In this open-label, randomised controlled trial, patients with RA …

Glucocorticoids have been available since the early 1950s and have since become an
integral part of the management of rheumatoid arthritis (RA). Due to their rapid effect …

Objective To estimate the incidence of infections among patients with psoriatic arthritis (PsA)
or axial spondyloarthritis (axSpA), two distinct phenotypes included in the large group of …

Tumor necrosis factor-α (TNFα) inhibitors are widely used in treating autoimmune diseases
like rheumatoid arthritis (RA). These inhibitors can presumably alleviate RA symptoms by …

Abstract Background Primary Sjögren's syndrome (pSS) is an autoimmune disease with
increased risk of infections. Here, we assessed whether pSS patients were at higher risk of …

Introduction Biologicals have become a cornerstone in rheumatoid arthritis (RA) treatment.
The increased risk of serious infections associated with their use is well-established. Non …

Introduction Disease-modifying anti-rheumatic drugs (DMARDs) have improved the
outcomes of patients with rheumatoid arthritis (RA). DMARDs are classified into three …